- Home
- ZIMV vs MIRM Comparison
ZIMV vs MIRM Comparison
Compare ZIMV & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZIMV
- MIRM
- Stock Information
- Founded
- ZIMV 2021
- MIRM 2018
- Country
- ZIMV United States
- MIRM United States
- Employees
- ZIMV N/A
- MIRM N/A
- Industry
- ZIMV Biotechnology: Electromedical & Electrotherapeutic Apparatus
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- ZIMV Health Care
- MIRM Health Care
- Exchange
- ZIMV Nasdaq
- MIRM Nasdaq
- Market Cap
- ZIMV 262.9M
- MIRM 1.9B
- IPO Year
- ZIMV N/A
- MIRM 2019
- Fundamental
- Price
- ZIMV $9.44
- MIRM $40.80
- Analyst Decision
- ZIMV Hold
- MIRM Strong Buy
- Analyst Count
- ZIMV 1
- MIRM 11
- Target Price
- ZIMV N/A
- MIRM $58.55
- AVG Volume (30 Days)
- ZIMV 141.2K
- MIRM 438.4K
- Earning Date
- ZIMV 05-08-2025
- MIRM 05-07-2025
- Dividend Yield
- ZIMV N/A
- MIRM N/A
- EPS Growth
- ZIMV N/A
- MIRM N/A
- EPS
- ZIMV N/A
- MIRM N/A
- Revenue
- ZIMV $449,749,000.00
- MIRM $336,888,000.00
- Revenue This Year
- ZIMV $2.13
- MIRM $29.51
- Revenue Next Year
- ZIMV $2.44
- MIRM $20.27
- P/E Ratio
- ZIMV N/A
- MIRM N/A
- Revenue Growth
- ZIMV N/A
- MIRM 80.76
- 52 Week Low
- ZIMV $8.56
- MIRM $23.83
- 52 Week High
- ZIMV $22.40
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- ZIMV 38.58
- MIRM 45.27
- Support Level
- ZIMV $9.25
- MIRM $38.22
- Resistance Level
- ZIMV $9.74
- MIRM $39.87
- Average True Range (ATR)
- ZIMV 0.58
- MIRM 2.27
- MACD
- ZIMV 0.12
- MIRM 0.23
- Stochastic Oscillator
- ZIMV 53.66
- MIRM 61.83
About ZIMV ZimVie Inc.
ZimVie Inc is focused on the dental and spine markets and their respective growth drivers such as implants, surgical tools, bone graft substitutes, spinal fusion implants, non-fusion alternatives, and digital care management solutions. Business is organized into two operating segments the spine products segment and the dental products segment.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.